28 February 2017
By A/Prof Miranda Xhilaga - PCFA Research Team
Enzalutamide (also known as MDV3100 and trading also as XTANDI) is a drug that binds to AR and in doing so, does not allow the translocation of AR to the cell nucleus, recruitment of other molecules that act in concert with AR and the binding of AR to DNA thus preventing proliferation of tumour cells. In other words, it blocks AR function so that tumour androgens are no longer active. A team of clinicians and researchers are currently looking at the effect of enzalutamide in men that have developed metastasis despite the use of ADT and that have not received chemotherapy.
To read the full article just log into the PCFA Online Community.
If you're not already a member, it is free and easy to join.
